Patient and Physician Knowledge of Key Safety Messages

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2227 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-15

Study Completion Date

2020-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

NCT02876718

Atrial Fibrillation

COMPLETED

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

NCT01947998

Venous Thrombosis Pulmonary Embolism Atrial Fibrillation +1 more

COMPLETED

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216

Peripheral Artery Disease

COMPLETED PHASE3

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

NCT02975453

Atrial Fibrillation

COMPLETED

Xarelto Regulatory Post-Marketing Surveillance

NCT01029743

Venous Thromboembolism

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anticoagulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type BEHAVIORAL

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

Group 2

Survey to measure patient awareness and understanding of the key messages in the patient card.

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type BEHAVIORAL

Survey to measure patient awareness and understanding of the key messages in the patient card.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

Intervention Type BEHAVIORAL

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure patient awareness and understanding of the key messages in the patient card.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Physician eligibility:

* Prescription of rivaroxaban in the past 6 months for adult patients for the Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT.

Patient eligibility:

* Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No